BC Innovations | Jul 27, 2017
Translation in Brief

Cycling across the membrane

In a Nature Chemistry study, a German team has shown that nanobodies coupled to cyclic peptides rich in arginine can target intracellular proteins with antibody-like precision and even deliver extracellular proteins to the cytosol. Delivering...
BC Innovations | Oct 9, 2014
Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse model of pain-associated anxiety and depression A mouse model of neuropathic pain could help identify therapeutics to treat pain-associated anxiety and depression. The model...
BioCentury | Apr 23, 2012
Emerging Company Profile

APIM: Besting the stress defense

Chemotherapies and other cancer drugs induce apoptosis by causing genotoxic and other cellular stresses, but the ability of cancer cells to overcome such stress can limit efficacy. By targeting a master regulator of cellular responses...
BC Innovations | Mar 22, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Proliferating cell nuclear antigen (PCNA) In vitro studies suggest the triiodothyronine T3 derivative PCNA inhibitor T2AA could help treat cancer. In vitro, T2AA inhibited...
BC Week In Review | Apr 20, 2009
Clinical News

AT7519: Phase I data

In a dose-escalation, international Phase I trial in patients with refractory solid tumors, 3.6-34 mg/m 2/day of IV AT7519 inhibited CDK as assessed by a reduction in phospho- nucleophosmin and proliferating cell nuclear antigen (PCNA)...
BC Extra | Dec 9, 2006
Clinical News

Breast cancer marker identified

Researchers at Indiana University and colleagues reported in the Proceedings of the National Academy of Sciences that they developed an antibody that detects a proliferating cell nuclear antigen isoform (caPCNA) associated with breast cancer epithelial...
BioCentury | Mar 14, 2005
Tools & Techniques

A different donut hole

The cell cycle is an important target for cancer therapies, as arrest of the cycle can stop proliferation and send cells into apoptosis. But developing drugs that target the cycle has been difficult without detailed...
BioCentury | Dec 22, 2003
Product Development

Around the circle

Until recently, Cyclacel Ltd. has disclosed its clinical pipeline piece by piece, which can make it hard to see how the company's overall development strategy fits together. But Cyclacel's approach to exploiting the cell cycle...
BC Week In Review | Apr 21, 2003
Clinical News

VIT100: Phase I

Immusol reported the start of a physician-sponsored U.S. Phase I study in 20 patients. Immusol Inc. , San Diego, Calif.   Product: VIT100   Business: Dermatology   Molecular target: Proliferating cell nuclear antigen (PCNA)   Description:...
BC Week In Review | Aug 19, 2002
Clinical News

VitrenAse: Phase II

Immusol began a double-blind U.S. Phase II trial of its VitrenAse to treat PVR, a condition characterized by uncontrolled cellular growth, retinal detachment and vision loss. The trial will assess safety and a reduction in...
Items per page:
1 - 10 of 16